Patent application number | Description | Published |
20100233200 | VECTOR ENCODING THERAPEUTIC POLYPEPTIDE AND SAFETY ELEMENTS TO CLEAR TRANSDUCED CELLS - A composition comprising: a stably integrating delivery vector; an modified mammalian thymidylate kinase (tmpk) activator polynucleotide wherein the modified mammalian tmpk polynucleotide encodings a modified mammalian tmpk polypeptide that increases phosphorylation of converts a prodrug relative to phosphorylation of the prodrug by wild-type mammalian tmpk polypeptide to a drug; and/or a targeting polynucleotide encoding a cell surface polypeptide that selectively binds a toxic binding agent. The disclosure also relates to use of these compositions in methods of treatment of diseases such as Fabry disease. | 09-16-2010 |
20100286046 | MODIFIED H2 RELAXIN FOR TUMOR SUPPRESSION - Modified H2 relaxms which act as antagonists of the relaxm receptor in cells and tissues, in particular, modified H2 relaxms comprising one or more alterations of the ammo acid sequence at positions B 13, B17 and B20 located in the receptor binding domain The antagonists retain affinity to the receptor, but do not substantially activate the receptor once bound thereto The H2 relaxm antagonists are used in compositions and methods for the treatment of cancers wherein a relaxm receptor is expressed | 11-11-2010 |
20100291043 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 11-18-2010 |
20110027310 | Compositions and Methods for Cancer Treatment - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer and prostate cancer. | 02-03-2011 |
20110104130 | THYMIDYLATE KINASE FUSIONS AND USES THEREOF - The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer. | 05-05-2011 |
20140093485 | THYMIDYLATE KINASE FUSIONS AND USES THEREOF - The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer. | 04-03-2014 |
20140193449 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT - Compositions and methods for delivering tumor associated antigens and immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer. | 07-10-2014 |
20140370039 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 12-18-2014 |